History of other malignancy that could affect compliance with the protocol or interpretation of results
Any medical condition or laboratory test abnormality that precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease, cardiovascular disease, and presence of an abnormal electrocardiogram (ECG)
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases or other disease with ongoing fibrosis
Have a second primary malignancy that in the judgment of the investigator or Lilly may affect the interpretation of results.
Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
Have known acute or chronic leukemia or current hematologic malignancies (except iNHL for patients in Part B) that, in the judgment of the investigator and sponsor, may affect the interpretation of results
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results (Part B only)
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
A second primary malignancy that in the judgment of the principal investigator (PI) or designee may affect the interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or contraindicate the use of an investigational drug, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy, autoimmune disease, or any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy, which could affect compliance with the protocol or interpretation of results
Second primary malignancy that may affect the interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
Have a second primary malignancy that in the judgment of the investigator and Medical Monitor may affect the interpretation of results.
Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Have a second primary malignancy that in the judgment of the investigator and medical monitor may affect the interpretation of results.
Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed.
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the participant
-  Evidence of any significant disease or condition that could affect compliance with the protocol or interpretation of results.
Have second primary malignancy that may affect the interpretation of results.
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
Evidence of significant uncontrolled concomitant disease that in the opinion of the investigator could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
Significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results